Demographics and selected characteristics of patients with autoimmune hepatitis (AIH) in the study cohort (n=420)
| Study participants (n=420) | |
| Age at survey completion (years) | 52±13 |
| Age at diagnosis of AIH (years) | 45±15 |
| Female | 92% |
| Race (%) | |
| Caucasian | 91 |
| African-American | 2 |
| Hispanic/Latino | 3 |
| Other | 4 |
| Fibrosis stage | |
| Cirrhosis | 23% (78/346) |
| Non-cirrhotic | 77% (268/346) |
| Unknown | 15% (62/408) |
| Liver transplantation | 3% |
| Current immunosuppressants (%) | |
| Predniso(lo)ne | 27 |
| Budesonide | 13 |
| AZA/6-MP | 62 |
| Mycophenolate mofetil | 18 |
| Tacrolimus | 8 |
| Sirolimus | 1 |
| None | 6 |
| Risk factors for severe COVID-19 illness (%) | |
| Hypertension | 27 |
| Over the age of 65 years | 16 |
| Asthma that requires the use of an inhaler | 12 |
| Severely overweight (BMI >40 kg/m2) | 12 |
| Prior cancer diagnosis | 9 |
| Diabetes mellitus type 2 | 8 |
| Chronic lung condition | 5 |
| Chronic kidney disease | 2 |
| Serious heart condition | 1 |
AZA, azathioprine; BMI, body mass index; 6-MP, 6-mercaptopurine.